Eli Lilly said its weight loss titan tirzepatide helped people lose up to 26% of their body weight, on average, across two late-stage clinical trials conducted over a year and a half, further setting the stage for the powerful new drug to soon receive FDA approval.
Lilly expects the FDA to hand down a decision on tirzepatide — which is approved as Mounjaro for type 2 diabetes — in weight loss by the end of the year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters